Remifentanil was designed to serve as a strong anesthetic with an ultra-short and predictable duration that would not have accumulation issues. Remifentanil is patented by Glaxo Wellcome Inc. and was FDA approved on July 12, 1996. Pricing for Ultiva. 1 mg vial - 30.19 USD; 3 mg vial - 57.20 USD; 5 mg vial - 118.15 USD
Breach of contract is a legal cause of action in which a binding agreement or bargained-for exchange is not honored by one or more of the parties to the contract by non-performance or interference with the other party's performance.
Breach of contract allows a party to bring the party in default to court and to get the court to correct the situation, as best the court can. The courts will intervene even if time for performance has not arrived where a side to a contract has given a clear indication that they do not intend on honouring the contract.